Immunology and Host Response: PDF OnlyClearance of Immunodeficiency-associated Vaccine-derived Poliovirus Infection With PocapavirCopelyn, Julie MMed*,†; Hincks, Jeffrey R. PhD‡; Wilmshurst, Jo M. MD§; Petersen, Wonita ND MedTech¶; Howard, Wayne MSc‖; Jallow, Sabelle PhD‖; Moonsamy, Shelina MSc‖; Seakamela, Lerato BTech‖; Suchard, Melinda MMed‖,**; Collett, Marc S. PhD‡; Eley, Brian MBChB*†Author Information From the *Paediatric Infectious Diseases Unit, Red Cross War Memorial Children’s Hospital †the Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa ‡ViroDefense, Inc., Chevy Chase, Maryland, U.S.A. §Department of Paediatric Neurology, Neuroscience Institute ¶Department of Paediatrics and Child Health, Red Cross War Memorial Children’s Hospital, University of Cape Town, Cape Town, South Africa ‖Centre for Vaccines and Immunology, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa **Chemical pathology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand. Accepted for publication December 8, 2019. The authors have no funding or conflicts of interest to disclose. Address for correspondence: Dr Julie Copelyn, MMed, Red Cross War Memorial Children's Hospital, Klipfontein Road,Rondebosch Cape Town 7700, South Africa. E-mail: firstname.lastname@example.org. The Pediatric Infectious Disease Journal: March 2, 2020 - Volume Online First - Issue - doi: 10.1097/INF.0000000000002584 Buy PAP Metrics Abstract Pocapavir exhibits antiviral activity against both polio and nonpolio enteroviruses. There is limited experience of the use of this investigational drug in young children with enteroviral infection. We describe the successful clearance of prolonged immunodeficiency-associated vaccine-derived type 3 poliovirus infection by pocapavir in an infant with underlying X-linked agammaglobulinemia. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.